9 results match your criteria: "France david.klatzmann@sorbonne-universite.fr.[Affiliation]"
A randomized double-blind placebo-controlled trial of low-dose interleukin-2 in relapsing-remitting multiple sclerosis.
J Neurol
September 2023
Immunology-Immunopathology-Immunotherapy (i3)-UMRS_959, Sorbonne Université- INSERM, Paris, France.
Background: Multiple sclerosis (MS) is associated with regulatory T cells (Tregs) insufficiency while low-dose interleukin-2 (IL2) activates Tregs and reduces disease activity in autoimmune diseases.
Methods: We aimed at addressing whether IL2 improved Tregs from MS patients. MS-IL2 was a single-center double-blind phase-2 study.
Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial.
Ann Rheum Dis
December 2022
Sorbonne Université-INSERM UMRS959, Immunology-Immunopathology-Immunotherapy (i3) laboratory, Sorbonne Universite, Paris, France
Objectives: A regulatory T cell (Treg) insufficiency due to shortage of interleukin-2 (IL-2) is central to the pathophysiology of systemic lupus erythematosus (SLE). We performed a multicentre, double-blinded, randomised, placebo-controlled phase II proof-of-concept trial to evaluate the efficacy of low-dose IL-2 therapy in patients with SLE having moderate-to-severe disease activity while receiving standard treatment.
Methods: We randomly assigned 100 patients in a 1:1 ratio to receive either 1.
Interleukin-2 and regulatory T cells in rheumatic diseases.
Nat Rev Rheumatol
December 2021
Sorbonne Université, INSERM, Immunology-Immunopathology-Immunotherapy (i3), Paris, France.
Failure of regulatory T (T) cells to properly control immune responses leads invariably to autoimmunity and organ damage. Decreased numbers or impaired function of T cells, especially in the context of inflammation, has been documented in many human autoimmune diseases. Restoration of T cell fitness and/or expansion of their numbers using low-dose natural IL-2, the main cytokine driving T cell survival and function, has demonstrated clinical efficacy in early clinical trials.
View Article and Find Full Text PDFImpaired Activated/Memory Regulatory T Cell Clonal Expansion Instigates Diabetes in NOD Mice.
Diabetes
April 2021
Sorbonne Universite, INSERM, UMRS959 Immunology-Immunopathology-Immunotherapy Laboratory, Paris, France
Article Synopsis
- Regulatory T cell (Treg) insufficiency in NOD mice leads to the destruction of insulin-producing β-cells by overactive Teffs, resulting in autoimmune diabetes.
- Analysis of TCR repertoires showed that NOD mice had greater Treg and Teff diversity compared to B6 mice, but lacked certain expanded clonotypes found in B6.
- IL-2 treatment in NOD mice restored the expansion of specific amTreg clonotypes, helping prevent diabetes, while having minimal impact on nTregs and Teffs, highlighting a potential therapeutic target for autoimmune diseases.
Low-dose IL-2 in children with recently diagnosed type 1 diabetes: a Phase I/II randomised, double-blind, placebo-controlled, dose-finding study.
Diabetologia
September 2020
Clinical Investigation Center for Biotherapies and Inflammation-Immunopathology-Biotherapy Department (i2B), AP-HP.Sorbonne Université, Pitié-Salpêtrière Hospital, 83 Bd de l'Hôpital, F-75013, Paris, France.
Article Synopsis
- The study focused on the effects of low-dose IL-2 on activating regulatory T cells (Tregs) in children with recently diagnosed type 1 diabetes, aiming to improve immune regulation over a year-long treatment.
- Conducted as a Phase I/II clinical trial, 24 children were randomly assigned to receive varying doses of IL-2 or placebo, with results measured primarily by the change in Tregs after 5 days.
- Results showed no serious side effects, with mild reactions mostly at the injection site; higher doses of IL-2 were associated with significant increases in Tregs compared to placebo.
Response to: 'Regulatory T cell frequencies in patients with rheumatoid arthritis are increased by conventional and biological DMARDs but not by JAK inhibitors' by Meyer .
Ann Rheum Dis
December 2021
AP-HP, Hôpital Pitié-Salpêtrière, Biotherapy (CIC-BTi) and Inflammation-Immunopathology-Biotherapy Department (i2B), F-75013, Paris, France, AP-HP, Paris, France
Response to: 'Circulating regulatory T cells were absolutelydecreased in dermatomyositis/polymyositispatients and restored by low-dose IL-2' by Zhang .
Ann Rheum Dis
August 2021
Sorbonne Université - INSERM UMRS959, Sorbonne Unversité, Paris, France
Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial.
Ann Rheum Dis
February 2019
Inflammation-Immunopathology-Biotherapy Department (i2B), AP-HP, Pitié-Salpêtrière Hospital, Paris, France
Objective: Regulatory T cells (Tregs) prevent autoimmunity and control inflammation. Consequently, any autoimmune or inflammatory disease reveals a Treg insufficiency. As low-dose interleukin-2 (ld-IL2) expands and activates Tregs, it has a broad therapeutic potential.
View Article and Find Full Text PDFIL-2 antibodies in type 1 diabetes and during IL-2 therapy.
Diabetologia
September 2018
AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Biotherapy (CIC-BTi) and Inflammation-Immunopathology-Biotherapy Department (i2B), Paris, France.